Kalaris Therapeutics, Inc. Common Stock (KLRS) is a publicly traded Healthcare sector company. As of May 21, 2026, KLRS trades at $4.83 with a market cap of $112.78M and a P/E ratio of -10.39. KLRS moved +3.09% today. Year to date, KLRS is -40.95%; over the trailing twelve months it is +45.05%. Its 52-week range spans $2.14 to $12.90. Analyst consensus is strong buy with an average price target of $15.75. Rallies surfaces KLRS's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Kalaris Therapeutics, Inc. Common Stock (KLRS) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. KLRS moved +3.09% today. Analyst consensus is strong buy.
| Metric | Value |
|---|---|
| Price | $4.83 |
| Market Cap | $112.78M |
| P/E Ratio | -10.39 |
| EPS | $-0.46 |
| Dividend Yield | 0.00% |
| 52-Week High | $12.90 |
| 52-Week Low | $2.14 |
| Volume | 0 |
| Avg Volume | 0 |
| Revenue (TTM) | $0 |
| Net Income | $-10.86M |
| Gross Margin | 0.00% |
5 analysts cover KLRS: 0 strong buy, 4 buy, 1 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $15.75.